Technology | Population Health | January 28, 2016

Boston Scientific and Accenture Develop Digital Health Solution for Chronic Cardiovascular Conditions

Care Pathway Transformation solution designed to help providers make better-informed decisions based on patient population insights

January 28, 2016 — Boston Scientific Corp. and Accenture have developed a cloud-based, data-driven digital health solution for hospitals to help improve patient outcomes and reduce costs to treat patients with chronic cardiovascular diseases.

The solution, known as Advantics Care Pathway Transformation, is designed to enable providers to make more proactive and informed decisions based on insights into the patient population. The goal ultimately is improving the care a patient experiences from hospital stay through post-discharge care and in-home support.

The Care Pathway Transformation solution uses the Accenture analytics insights platform, which provides actionable insights into care coordination and patient population health patterns, revealing opportunities to improve their consistency and efficiency. The solution will focus on three key measurements:

  • Pathway Analytics: how a patient moves through the hospital system, how long each step takes and whether a patient can be better served by a more efficient system;
  • Care Management: how patients are diagnosed, treated and monitored, by whom and how often, as well as their ongoing vital signs and risk analysis; and
  • Patient Engagement: how patients are educated, monitored and receive communication during their hospitalization and after discharge.

The solution has been tailored for insight into patients with heart failure, but the companies plan to expand it to additional disease states.

In developing this solution, both companies worked with two of the largest hospitals in Scandinavia — Karolinska University Hospital in Sweden and Tampere Heart Hospital in Finland — to assess the current state of care delivery for heart failure patients and identify opportunities for improvement at each hospital. Heart failure has been identified as one of the costliest disease states to manage — resulting in about 2 percent of healthcare spending and accounting for an average 11-day hospital stay in Europe.

"The collaboration with Boston Scientific and Accenture exposed significant opportunities to increase provider collaboration and improve the quality of care that patients experience when coming to our hospital," said Kari Niemelä, M.D., chief executive officer, Tampere Heart Hospital. "For example, we identified a 25 percent unnecessary heart failure readmissions rate, and therefore a definite need for better care coordination, supported by modern technology and processes that can decrease overall costs."

The two companies initially plan to make the Care Pathway Transformation solution available to hospitals in the United Kingdom and Scandinavia, and expect to pilot projects throughout Europe and the United States soon.

For more information: www.bostonscientific.com, www.accenture.com

Related Content

First Patient Enrolled in U.S. Arm of ALIVE Pivotal Heart Failure Trial
News | Heart Failure| October 17, 2017
October 17, 2017 — BioVentrix Inc. recently announced enrollment of the first patient in the U.S.
Philips IntelliSpace cardiovascular information system (CVIS)

The Philips IntelliSpace is an example of the newer generation of cardiovascular information systems (CVIS) that can consolidate all cardiology department data sources into one location.

Feature | Cardiac PACS| October 04, 2017 | Dave Fornell
Consolidation of data in one location to improve efficiency and enable data analytics, as well as smooth integration
Medtronic HeartWare HVAD System Approved for Destination Therapy
Technology | Ventricular Assist Devices (VAD)| October 04, 2017
October 4, 2017 — Medtronic received U.S.
Medical Metrics Taps Digisonics Cardiovascular Information Systems for Clinical Trials
News | Cardiac PACS| October 03, 2017
October 3, 2017 – Medical Metrics, an experienced core laboratory for multi-center clinical trials, has implemented t
AstraZeneca HealthCare Foundation Awards 2017 Connections for Cardiovascular Health Grants
News | Patient Engagement| September 28, 2017
September 28, 2017 — The AstraZeneca HealthCare Foundation’s Connections for Cardiovascular Health (CCH) program is a
Abiomed Receives FDA PMA Approval for Impella RP for Right Heart Failure
Technology | Ventricular Assist Devices (VAD)| September 28, 2017
Abiomed Inc. recently received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP ...
Boston Scientific Launches Resonate Devices With HeartLogic Heart Failure Diagnostic
Technology | Implantable Cardioverter Defibrillator (ICD)| September 27, 2017
September 27, 2017 — Boston Scientific recently launched the Resonate family of...
BioCardia Announces 12-Month Results from TRIDENT Trial of Stem Cell Delivery System
News | Stem Cell Therapies| September 26, 2017
BioCardia Inc. recently announced 12-month results from the Phase II TRIDENT clinical trial, conducted by the...
CardiAMP Heart Failure Trial Design Presented at Texas Heart Institute Symposium
News | Heart Failure| September 25, 2017
BioCardia Inc. announced the trial design for its pivotal Phase III CardiAMP Heart Failure Trial was presented during...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
Overlay Init